ArticleNPJ breast cancer2025
Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab.
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.Breast (Edinburgh, Scotland) · 2026Observational
- Impact of HER2 immunohistochemistry score on pathological complete response and survival in HER2-positive breast cancer treated with neoadjuvant therapy: differential outcomes by hormone receptor status.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Weekly paclitaxel and trastuzumab (APT regimen) represents the standard treatment for most stage I HER2+ breast cancer (BC) patients based on results of the single arm phase II APT trial. Confirmation of long-term outcomes in real-world cohorts is of interest. This retrospective study included patients with early HER2 + BC (pT ≤ 3 cm; pN0/N1mic) treated with APT regimen. This study included 276 patients; most presented hormone receptor (HR) positive (75%, N = 207) and grade 3 tumors (65.6%, N = 181). The majority had pT ≤ 2 cm (92.4%, N = 255), no nodal involvement (93.1%, N = 257), with only 19 patients (6.9%) presenting N1mic. Anatomical stage was: IA 86.2% (N = 238), IB 6.2% (N = 17), and IIA 7.6% (N = 21). At a median follow-up of 4.4 years, 3-year recurrence free survival (RFS) was 97.3% (95% CI 95.1-99.5), 3-year distant relapse free survival (DRFS) was 98.2% (95% CI 96.4-100), and 3-year invasive breast cancer free survival (IBCFS) rate was 97.1% (95% CI 94.7-99.5). A statistically significant difference in RFS was observed according to anatomical stage ( p < 0.001). This real-world study confirms that APT regimen is associated with excellent outcomes in stage IA HER2 + BC patients, while caution is warranted for patients with stage IB or IIA disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.